Alprazolam

證據等級: L5

預測適應症: 3 個

Alprazolam: From Anxiety / Panic Disorder to Insomnia

One-Sentence Summary

Alprazolam is a benzodiazepine widely used internationally for anxiety disorders and panic disorder, acting by enhancing inhibitory GABA-A neurotransmission throughout the central nervous system. The TxGNN model predicts it may be effective for Insomnia, with a prediction confidence of 99.81%; however, no direct clinical trial or published literature currently confirms alprazolam as a primary insomnia treatment, placing current evidence at Level 4 (mechanism-based only).

Quick Overview

Item	Content
Original Indication	Anxiety disorder / Panic disorder
Predicted New Indication	Insomnia (disease)
TxGNN Prediction Score	99.81%
Evidence Level	L4
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Alprazolam is a triazolobenzodiazepine that potentiates GABA-A receptor-mediated chloride ion influx, increasing central inhibitory tone. This mechanism directly shortens sleep-onset latency and increases total sleep time — properties that are pharmacologically relevant to insomnia. The prediction is mechanistically sound: sleep and anxiety disorders both involve hyperarousal driven by GABA/glutamate imbalance and HPA axis dysregulation, and benzodiazepines have historically been used across both indications.

However, clinical suitability for insomnia is limited in practice. Shorter-acting Z-drugs (e.g., zolpidem) and low-dose sedating antidepressants are generally preferred for sleep induction; alprazolam’s intermediate half-life (~11 hours), high abuse liability, and Schedule-controlled status place it well below first-line. Importantly, chronic use suppresses slow-wave sleep (SWS) and REM sleep, which can worsen overall sleep quality over time despite short-term benefit.

From a South African perspective, the primary barrier is regulatory: alprazolam has no SAHPRA registration and is not marketed in South Africa. Even if evidence were stronger, a formal new drug application would be required before any clinical deployment. Modern insomnia management guidelines — including those aligned with WHO recommendations relevant to South African primary care — prioritise Cognitive Behavioural Therapy for Insomnia (CBT-I) as first-line, with pharmacotherapy as adjunctive only.

Clinical Trial Evidence

The 7 trials retrieved for the alprazolam + insomnia query are largely tangential. None directly evaluates alprazolam as a primary treatment for chronic insomnia; they address BZD cessation, perioperative sedation, or different drugs entirely.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02648776	N/A	Unknown	1,400	Prospective cohort (Taiwan) examining risk-benefit of hypnotics including benzodiazepines in elderly patients with sleep disorders; assesses efficacy, safety, pharmacokinetics and pharmacogenetics — the most relevant trial for the BZD-insomnia question, but status is unknown
NCT00266409	Phase 4	Completed	418	Niravam™ (alprazolam ODT) combined with newly initiated SSRI/SNRI vs SSRI/SNRI alone in patients with GAD or panic disorder; anxiety-focused, not insomnia-focused
NCT04572750	N/A	Completed	170	Electronic self-management programme to promote BZD cessation in US Veterans; cessation direction is opposite to evaluating insomnia efficacy — provides safety/dependence background only
NCT03327506	Phase 4	Unknown	128	Hypnosis vs alprazolam premedication for perioperative anxiety in gynaecological surgery; acute sedation, not chronic insomnia treatment
NCT01584440	Phase 2	Completed	220	AVP-923 (dextromethorphan/quinidine) for agitation in Alzheimer’s disease; different drug and different indication
NCT01146600	Phase 2	Completed	26	Clarithromycin for hypersomnia (excessive sleepiness); different drug and opposite sleep disorder
NCT01893632	Phase 2	Terminated	2	Gabapentin for BZD dependence treatment; terminated early with only 2 participants enrolled — highlights BZD dependence risks rather than insomnia efficacy

Literature Evidence

Currently no related literature directly evaluating alprazolam for insomnia is available.

South Africa Market Information

Alprazolam is not currently registered with SAHPRA and is not marketed in South Africa. No product licences are on record, and no dosage forms are available through registered channels. This constitutes a significant regulatory barrier: clinical use would require either a Section 21 unregistered medicine authorisation (for individual patients) or a full SAHPRA new drug application for any systematic repurposing programme.

Healthcare professionals considering use under Section 21 should note that alprazolam is internationally classified as a controlled substance (Schedule IV in the USA; equivalent scheduling would apply in South Africa under the Medicines and Related Substances Act).

Safety Considerations

Alprazolam has no SAHPRA-approved Professional Information (PI). Prescribers should consult the manufacturer’s international prescribing information (FDA label, EMA SmPC). Based on internationally recognised data, the following are key considerations:

Dependence and withdrawal: Physical dependence develops with regular use beyond 2–4 weeks; abrupt discontinuation can precipitate withdrawal seizures, requiring gradual taper
Sedation and psychomotor impairment: Falls, road traffic accidents, and cognitive impairment are significant risks, particularly in patients over 65
Sleep architecture disruption: Chronic use suppresses slow-wave sleep and REM sleep — potentially worsening the very condition being treated
Respiratory depression: Risk is substantially increased when co-administered with opioids, alcohol, or other CNS depressants; potentially fatal combinations
Anterograde amnesia: Documented in controlled studies with agoraphobia/panic patients receiving alprazolam

Report any adverse drug reactions to SAHPRA at https://www.sahpra.org.za.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction is mechanistically plausible — alprazolam’s GABA-A enhancement does produce sedative-hypnotic effects relevant to insomnia. However, no dedicated clinical trial or published literature directly supports alprazolam for insomnia as a primary indication, evidence remains at L4 (mechanism-based only), and the drug has no SAHPRA registration in South Africa. Proceeding without stronger evidence and regulatory standing would not meet standard of care requirements.

Important secondary finding: The TxGNN model also predicted alprazolam for Agoraphobia (rank 3, TxGNN score 99.56%), which carries L1 evidence — supported by multiple completed multicentre RCTs published in Archives of General Psychiatry (1988), the British Journal of Psychiatry (1993, 1994), and a 2011 meta-analysis in Journal of Clinical Psychopharmacology — with a recommendation of Proceed with Guardrails. This indication is a substantially more actionable repurposing opportunity and warrants a dedicated evaluation report.

To proceed with the insomnia indication, the following is needed:

Initiate SAHPRA registration (via new drug application or Section 21 pathway) as the primary regulatory prerequisite
Commission a dedicated Phase 2/3 RCT directly evaluating alprazolam for chronic insomnia against standard-of-care comparators (CBT-I, zolpidem, low-dose doxepin)
Obtain complete mechanism of action and full prescribing information via DrugBank API and manufacturer data
Conduct comparative effectiveness review vs. non-BZD insomnia options, including cost-effectiveness analysis relevant to the South African public health context
Establish a robust dependence monitoring and pharmacovigilance plan prior to any patient exposure, with particular attention to high-risk groups (elderly, those with prior substance use disorders)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.